Pharmaceuticals

This channel includes news and new technology innovations for cardiovascular pharmaceutics. This includes antiplatelet agents, anticoagulation drugs, INR testing, NOAC, OAC, IV administered drugs such as Heprin, and dual antiplatelet therapy.

Stopping statin treatment early could substantially reduce lifetime protection against heart disease since a large share of the benefit occurs later in life

News | Pharmaceuticals

Study Highlights Lifelong Benefits of Statin Therapy

September 6, 2022 — Stopping statin treatment early could substantially reduce lifetime protection against heart disease ...

September 06, 2022

SECURE trial presented in a Hot Line Session today at ESC Congress 2022

News | ESC

Polypill Reduces Cardiovascular Events in Heart Attack Patients Compared to Usual Care

August 30, 2022 — A pill containing aspirin and medications to lower lipids and blood pressure more effectively prevents ...

August 30, 2022

As the cardiology community commemorates the importance of heart health on World Heart Day, Sept. 29, here’s a quick look back in heart history at four individuals who earned their place in the National Inventors Hall of Fame

Feature | Cardiovascular Business | By Christine Book

At the Intersection of History and Heart Health: Inventors Hall of Fame Inductees

As the cardiology community commemorates the importance of heart health on World Heart Day, Sept. 29, here’s a quick ...

August 18, 2022

Trial was negatively impacted by the COVID-19 pandemic and did not meet the primary endpoint

News | Pharmaceuticals

dal-GenE Phase 3 Cardiovascular Precision Medicine Outcomes Trial Results Published in European Heart Journal

July 25, 2022 DalCor Pharmaceuticals announced the results of the dal-GenE Phase 3 cardiovascular precision medicine ...

July 25, 2022

Amarin Corporation plc announced that research on the potential population health impact and cost-effectiveness of VASCEPA (icosapent ethyl), presented in two poster presentations at the American Heart Association’s Quality of Care and Outcomes Research Scientific Sessions in Reston, VA, May 13-14, 2022

News | Pharmaceuticals

Research Presented at AHA's QCOR Scientific Sessions Indicate Potential for Vascepa to Reduce Major Adverse CV Events

May 24, 2022 — Amarin Corporation plc announced that research on the potential population health impact and cost ...

May 24, 2022

The U.S. Food and Drug Administration (FDA) has issued a statement that Teva Pharmaceuticals USA has initiated a voluntary nationwide recall of a single lot of Anagrelide Capsules, USP 0.5 mg (Lot number GD01090), to the consumer level in the United States.

News | Pharmaceuticals

Teva Issues Voluntary Nationwide Recall of One Lot of Anagrelide Capsules

May 24, 2022 — The U.S. Food and Drug Administration (FDA) has issued a statement that Teva Pharmaceuticals USA has ...

May 24, 2022

Research Presented at the American Heart Association’s Quality of Care and Outcomes Research (QCOR) Scientific Sessions Indicate Potential for VASCEPA (icosapent ethyl) to Reduce Major Adverse Cardiovascular (CV) Events and Associated Costs

News | Pharmaceuticals

Research Shows Potential to Reduce Major Cardiovascular (CV) Events

May 17, 2022 — Amarin Corporation plc announced that research on the potential population health impact and cost ...

May 17, 2022

Mavacamten estimated sales just shy of $1 billion if approved for common cardiomyopathy subtype, says GlobalData

News | Pharmaceuticals

Bristol Myers Squibb’s Mavacamten Poised to Stand unchallenged

May 13, 2022 — Bristol Myers Squibb’s mavacamten will stand rather unchallenged in the hypertrophic cardiomyopathy (HCM) ...

May 13, 2022

$Results from the DELIVER and DAPA-HF Phase III trials demonstrate FARXIGA’s efficacy in heart failure regardless of ejection fraction$

News | Cardiovascular Clinical Studies

FARXIGA Met Primary Endpoint in DELIVER Phase III Trial

May 5, 2022 — High-level results from the DELIVER Phase III trial showed AstraZeneca’s FARXIGA (dapagliflozin) reached a ...

May 05, 2022

Approval based on groundbreaking Phase 3 EXPLORER-HCM trial demonstrating benefit in patients receiving Camzyos versus placebo

News | Pharmaceuticals

FDA Approves Bristol Myers' Camzyos (mavacamten) Oral Heart Disease Drug

April 29, 2022 — Bristol Myers Squibb announced that the U.S. Food and Drug Administration (FDA) approved Camzyos ...

April 29, 2022

News | Heart Failure

Mavacamten Dramatically Cuts Need for Surgical Intervention for People with Obstructive Hypertrophic Cardiomyopathy

April 12, 2022 – A majority of patients with obstructive hypertrophic cardiomyopathy (HCM)—a condition that results in ...

April 12, 2022

Patients taking renin-angiotensin-aldosterone system inhibitor (RAASi) medications for heart failure had significantly lower blood potassium levels when taking patiromer—a drug that helps to prevent the body from absorbing too much potassium—compared with a placebo, in a study presented at the American College of Cardiology’s 71st Annual Scientific Session.

News | Heart Failure

Patiromer Helps Patients Stay on Optimal Heart Failure Therapy

April 8, 2022 – Patients taking renin-angiotensin-aldosterone system inhibitor (RAASi) medications for heart failure had ...

April 08, 2022

News | Structural Heart

No Reduction in Stroke, Mini Strokes, Blood Clotting in the Brain or Changes in Cognitive Function with Edoxaban After TAVR

April 7, 2022 – Patients treated with the blood thinner edoxaban for six months after a heart valve replacement ...

April 07, 2022

News | Cardiovascular Clinical Studies

SLN360 Markedly Reduces Lipoprotein(a), an Important Cause of Heart Disease

April 7, 2022 – While there are effective therapies to reduce the risk of heart disease by lowering low-density ...

April 06, 2022

News | ACC

Esperion Announces Two NEXLETOL Data Presentations at ACC.22

April 4, 2022 – Esperion presented two new analyses from its clinical development program of bempedoic acid (NEXLETOL) ...

April 04, 2022